68Ga-Trivehexin PET/CT: a promising novel tracer for primary hyperparathyroidism,European Journal of Nuclear Medicine and Molecular Imaging

当前位置： X-MOL 学术 › Eur. J. Nucl. Med. Mol. Imaging › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

68Ga-Trivehexin PET/CT: a promising novel tracer for primary hyperparathyroidism
European Journal of Nuclear Medicine and Molecular Imaging ( IF 8.6 ) Pub Date : 2024-07-19 , DOI: 10.1007/s00259-024-06846-z
Serkan Kuyumcu ₁ , Dilara Denizmen ₁ , Duygu Has-Simsek ₁ , Arzu Poyanli ₂ , Ayşe Kubat Uzum ₃ , Fikret Buyukkaya ₁ , Emine Goknur Isik ₁ , Semen Onder ₄ , Nihat Aksakal ₅ , Zeynep Gozde Ozkan ₁ , Yasemin Sanli ₁

Affiliation

Introduction

This study aims to assess ⁶⁸Ga-Trivehexin PET/CT for detecting hyperfunctioning parathyroid tissue in comparison to [^99mTc]Tc-MIBI scintigraphy-SPECT/CT (MIBI scan) in patients with primary hyperparathyroidism (PHPT).

Methods

The cohort comprised 13 patients diagnosed with PHPT based on biochemical analyses, including serum calcium, phosphorus, and parathyroid hormone (PTH) levels. Each participant underwent cervical ultrasonography, MIBI scan, and ⁶⁸Ga-Trivehexin PET/CT imaging. Complementary 4D-CT and [¹⁸F]fluorocholine PET/CT were conducted in 7 patients. Ten lesions of 7 patients underwent PTH wash-out (WO) procedure. ⁶⁸Ga-Trivehexin PET/CT findings were compared with other modalities and PTH-WO results.

Results

Ten patients had sporadic PHPT, while 3 were diagnosed with MEN-1 syndrome-associated PHPT. One patient did not have any identifiable parathyroid lesion across the imaging modalities. On a patient-based analysis, MIBI scan and ⁶⁸Ga-Trivehexin PET/CT identified parathyroid lesions in 10 and 11 patients, respectively. However, ⁶⁸Ga-Trivehexin PET/CT detected 7 additional parathyroid lesions that were negative on the MIBI scan. Consequently, 17 lesions were identified and confirmed as hyperfunctioning parathyroid tissue through imaging, PTH-WO, or a combination of both modalities. In lesion-based evaluation, ⁶⁸Ga-Trivehexin identified 16 lesions compared to 10 by MIBI scan, resulting in a detection rate of 94.1% and 58.8%, respectively. Notably, in three patients who underwent [¹⁸F]fluorocholine PET/CT, no lesions were detected; yet ⁶⁸Ga-Trivehexin PET/CT successfully identified parathyroid lesions in two of these patients.

Conclusion

Our study provides the first evidence that ⁶⁸Ga-Trivehexin PET/CT can effectively identify hyperfunctioning parathyroid tissue with a high detection rate warranting further investigations to comprehensively explore its potential in PHPT management.

中文翻译：

68Ga-Trivehexin PET/CT：一种很有前途的原发性甲状旁腺功能亢进症的新型示踪剂

介绍

本研究旨在评估 ⁶⁸个 Ga-Trivehexin PET/CT 与原发性甲状旁腺功能亢进症（PHPT）患者与 [^99mTc]Tc-MIBI 闪烁显像-SPECT/CT（MIBI 扫描）相比检测功能亢进的甲状旁腺组织的作用。

方法

该队列包括 13 名根据生化分析诊断为 PHPT 的患者，包括血清钙、磷和甲状旁腺激素（PTH）水平。每位参与者都接受了宫颈超声检查、MIBI 扫描和 ⁶⁸例 Ga-Trivehexin PET/CT 成像。对 7 例患者进行了互补 4D-CT 和 [¹⁸F] 氟胆碱 PET/CT。7 例患者的 10 个病灶接受了 PTH 清除（WO）手术。⁶⁸将 Ga-Trivehexin PET/CT 结果与其他方式和 PTH-WO 结果进行比较。

结果

10 例患者为散发性 PHPT，3 例诊断为 MEN-1 综合征相关 PHPT。1 例患者在影像学检查中没有任何可识别的甲状旁腺病变。在基于患者的分析中，MIBI 扫描和 ⁶⁸Ga-Trivehexin PET/CT 分别在 10 例和 11 例患者中发现了甲状旁腺病变。然而，⁶⁸个 Ga-Trivehexin PET/CT 检测到另外 7 个甲状旁腺病变，MIBI 扫描呈阴性。因此，通过影像学、PTH-WO 或两种方式的组合确定并确认 17 个病灶为功能亢进的甲状旁腺组织。在基于病灶的评估中，⁶⁸个 Ga-Trivehexin 识别出 16 个病灶，而 MIBI 扫描识别出 10 个病灶，检出率分别为 94.1% 和 58.8%。值得注意的是，在接受 [¹⁸F] 氟胆碱 PET/CT 的 3 例患者中，未检测到病变;然而，⁶⁸个 Ga-Trivehexin PET/CT 成功识别了其中两名患者的甲状旁腺病变。